CVS Health - CVS Health experienced a rebound in 2025, with improved financial results and raised guidance for revenue, operating income, and earnings per share for 2026 [3][4] - The company is addressing challenges such as rising costs and shrinking operating margins, particularly in its Medicare Advantage business, by significantly rolling back this segment to focus on profitable growth [4][5] - CVS Health is currently trading at 11.2 times forward earnings, which is below the healthcare sector average of 18.4, indicating reasonable valuation [5] - The company has a vast network of pharmacies and diversified healthcare operations, which provide significant advantages as healthcare spending increases [6] - CVS Health has adapted to competition, notably from Amazon, by offering free and fast delivery services for prescription medications, making it a strong long-term investment [7] - The outlook for CVS Health in 2026 and beyond appears promising, especially for dividend-seeking investors [8] Amgen - Amgen is developing new drug products to address a recent patent cliff, positioning itself for future growth [8]

Core Viewpoint - WW International's shares increased nearly 6% in premarket trading following the announcement of a new partnership with Amazon to deliver GLP-1 weight-loss drugs and other prescription medications [1] Company Summary - WW International has formed a partnership with Amazon to enhance the delivery of GLP-1 weight-loss drugs and other prescription medications [1] Market Reaction - The announcement led to a nearly 6% rise in WW International's shares during premarket trading on Monday [1]

Drug Pricing & Accessibility - Pfizer commits to offering all prescription medications to Medicaid at most favored nation prices, aiming to significantly reduce Medicaid costs [1] - Pfizer agrees to provide some popular medications to all consumers at heavily discounted prices, ranging from 50% to 100% off, available for direct purchase online via a federal government website [2] - All new medications introduced by Pfizer to the American market will be sold at reduced most favored nation costs, aligning with prices paid by other countries [3] - The agreement aims to bring down drug prices immediately for Americans [8] Manufacturing & Investment - Pfizer will invest $70 billion to reshore domestic manufacturing facilities, relocating production to the United States [3][4] - Pfizer commits to source the production of medicines consumed in the US from within the US, unleashing its investment portfolio in the country [5] - Pfizer is granted a three-year grace period from tariffs as long as they move production to the US [5] Negotiation & Tariffs - The administration is negotiating deals with other companies, with Pfizer being the first [6] - The administration is prepared to impose tariffs of an equivalent amount if companies refuse to make a deal, removing the advantage of non-compliance [7]

Pricing & Accessibility - Fiser commits to offering all prescription medications to Medicaid at most favored nation's prices, aiming to reduce Medicaid costs [1] - Fiser agrees to provide some popular medications to all consumers at heavily discounted prices, ranging from 50% to 100% off [1][2] - All new medications introduced by Fiser to the American market will be sold at reduced most favored nation costs [3] Investment & Manufacturing - Fiser will invest $70 billion to reshore domestic manufacturing facilities [3][4] - The investment will fund research and development in America [4] Industry Impact - The agreement aims to secure similar agreements with other major pharmaceutical companies [4]